Evidence map›Paper›PMID 37041585›Full record

ArticleOrphanet journal of rare diseases2023

A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases.

Ania Korsunska, Mileva Repasky, Mary Zuccato, David C Fajgenbaum

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Rare Disease Drug Repurposing.JAMA network open · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ania KorsunskaSyracuse University, 343 Hinds Hall, Syracuse, NY, 13244, USA. info@castlemannetwork.org.ORCID 0000-0003-3158-8436
Mileva RepaskyCastleman Disease Collaborative Network, 3535 Market Street, Suite 700, Philadelphia, PA, 19104, USA.
Mary ZuccatoCastleman Disease Collaborative Network, 3535 Market Street, Suite 700, Philadelphia, PA, 19104, USA.
David C FajgenbaumCastleman Disease Collaborative Network, 3535 Market Street, Suite 700, Philadelphia, PA, 19104, USA.
BioTelemetry (United States) · US

Funding

ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman DiseaseR01FD007632 · FDA · UNIVERSITY OF PENNSYLVANIA · PI Joshua D. Brandstadter, David C Fajgenbaum · 2022 to 2026
$2.2M
FDA HHS R01 FD007632
6 · The paper itself

Abstract

backgroundThere are approximately 10,000 rare diseases that affect around 30,000,000 individuals in the U.S.A., most of which do not have an FDA-approved treatment. This fact highlights the failure of traditional research approaches to overcome the unique challenges of developing rare disease treatments. The Castleman Disease Collaborative Network was founded in 2012 to advance research and treatments for Castleman disease, a rare and deadly disease that involves the immune system attacking the body's vital organs for an unknown cause. It has spearheaded a novel strategy for advancing biomedical research, the Collaborative Network Approach. This approach consists of eight steps, one of which is to identify and prioritize high-impact research questions through crowdsourcing ideas from the entire community of stakeholders: patients, loved ones, physicians, and researchers. Rather than hoping that the right researcher will apply for the right research project at the right time, crowdsourcing high-priority research projects into a research strategy ensures that the most high-impact, patient-centered studies are prioritized. The Castleman Disease Collaborative Network launched an initiative in 2021 to systematically generate this list of community-directed studies to focus Castleman disease research efforts.

resultsThe Castleman Disease Collaborative Network was able to successfully create a patient-centered research agenda through engaging the entire community of stakeholders. The community contributed important questions about Castleman disease, which were prioritized and reviewed by our Scientific Advisory Board, and the result was a finalized list of studies that address these prioritized questions. We were also able to generate a best practices list which can serve as a model that can be utilized for other rare diseases.

conclusionCreating a patient-centered research agenda through crowdsourcing research ideas from the community is one of the most important ways that the Castleman Disease Collaborative Network operationalizes its commitment to keeping patients at the center of research and we hope that by sharing these insights we can assist other rare disease organizations to pursue a patient-centric approach.

Indexed as

Biomedical ResearchCastleman DiseaseCrowdsourcingHumansRare DiseasesResearch DesignCastleman diseaseCollaborative networkCrowdsourcingPatient-centered research agendaRare disease

Identifiers

PMID37041585
PMCPMC10091676
OpenAlexW4364379627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.